Big Changes for USP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Changes for USP
Feedback is urged on USP's proposed revisions to the General Notices.


Pharmaceutical Technology



Neil Schwarzwalder
The United States Pharmacopeia (USP) is in the process of completely rewriting the General Notices and Requirements sections of the USP and National Formulary (NF), to become effective in 2009. The General Notices provide a framework for interpreting and applying requirements for the USP-NF, so these revisions affect every monograph, general test, and requirement.

Because of the potential impacts on testing and compliance, these revisions require careful evaluation by pharmaceutical manufacturers, their suppliers, and contractors. Timely industry review of the proposal is needed to meet the ambitious timeline planned by USP for review and implementation.




The most visible changes to the General Notices are a completely revised format and a new numbering system intended to improve clarity and user-friendliness. This restructuring will make it easier to find information on alternative methods, controlling impurities, quality of water for testing and manufacturing, labeling, and other topics crucial for appropriate application of the USP and NF. Although there is little intentional change in meaning for most of these topics, changes in context and unintended alterations in meaning are possible.

Significant changes in content are also proposed, including a plan to share the same General Notices for five different publications. In addition to the USP and NF, USP now publishes the Food Chemicals Codex (FCC) and two online publications:
  • Standards for Articles Legally Marketed Outside of the US (SALMOUS or S-USP), intended for international pharmaceuticals
  • Pending Standards, intended for pharmaceuticals pending approval by the US Food and Drug Administration.

Adopting the same General Notices for all of these publications requires careful consideration to ensure their appropriate use.

Another major change concerns a new definition of official, which may affect the regulatory status of articles and interpretation of requirements. Because the term official compendium is defined in the Food, Drug and Cosmetic (FD&C) Act to include the USP and NF, but not the other publications, care is needed to avoid confusion. In a related initiative, USP is also considering changing the status of some general chapters, so that some non-mandatory sections might be made mandatory, and vice versa.

The URL ( http://www.usp.org/USPNF/generalNotices.html) links to the revisions of both the USP-NF and the FCC General Notices and describes the timeline for review and comment.

Industry participation urged

Industry members are encouraged to review the revised USP General Notices with experts in their organizations to identify areas of concern and provide comments to USP. In addition, a project team sponsored by the USP invites feedback from affected parties to formulate a detailed user response to the proposed revisions.


General Notices Project Team .
The General Notices Project Team was established "to open a dialogue between stakeholders and USP and to review the USP-NF General Notices related to content and considerations for rearranging its presentation." The project team (see box) brings together considerable expertise. The team welcomes constructive feedback and alternative proposals from other stakeholders.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here